Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2018-12-03 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
CP en français
Earnings Release Classification · 95% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces new clinical data presented at the 'CONGRÈS ANNUEL DE LA SOCIÉTÉ AMERICAINE D'HÉMATOLOGIE (ASH) 2018'. It also announces a future conference call and the initiation of a Phase II study. This structure—announcing results and providing details about a presentation/call—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on clinical trial results and future development plans rather than comprehensive quarterly financial performance (which would suggest IR or 10-K), and it is a formal press release announcing key data points, the most appropriate classification is Earnings Release (ER), as these often include operational and clinical milestones for biotech/pharma companies. It is not a full transcript (CT), a formal annual report (10-K), or just a notice of a report publication (RPA), as it contains substantial content about the results themselves. FY 2018
2018-12-03 French
PR in English
Regulatory Filings Classification · 94% confidence The document is a press release from Innate Pharma dated November 30, 2018, announcing the publication of research data regarding their drug monalizumab in the journal 'Cell'. It details scientific findings, clinical trial progress (Phase II), and strategic partnerships. This type of announcement, focusing on scientific milestones, research publications, and clinical updates, is characteristic of investor relations communication, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a formal announcement of a significant event (publication in a major journal) intended for investors and the public, and it doesn't fit the specific categories like DIV, CAP, or MANG, it falls best under the general category for regulatory/investor announcements that aren't strictly financial reports or specific corporate actions. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard corporate news releases that are not explicitly defined elsewhere, although 'Investor Presentation' (IP) or 'Management Reports' (MDA) might seem related to the content, the format is a press release announcing external validation (journal publication), making RNS the most appropriate fallback for a significant, non-financial-reporting announcement.
2018-11-30 English
CP en français
Regulatory Filings Classification · 95% confidence The document is titled "INNATE PHARMA ANNONCE LA PUBLICATION..." and explicitly states that research work on Monalizumab has been published in the scientific journal 'Cell'. The text is a press release dated November 30, 2018, announcing the publication of scientific findings and referencing clinical trials. It is not a full financial report (10-K or IR), an earnings release (ER), or a transcript (CT). Since it is an announcement about the publication of scientific data/results, it fits best under the general category of regulatory/corporate announcements. Given the options, and since it is not a formal financial filing, a management change, or a dividend notice, it is classified as a general Regulatory Filing (RNS), as it is a formal communication to the market about a significant development (scientific publication and clinical progress). It is not an announcement *of* a report release (RPA), but the content itself is a scientific/corporate update.
2018-11-30 French
CP en français
Board/Management Information Classification · 99% confidence The document is a press release dated November 20, 2018, announcing the appointment of six experts to Innate Pharma's new Strategic Advisory Board (SAB). The content focuses entirely on management/advisory appointments and the expertise of the new members, which directly relates to the company's scientific and strategic direction. This aligns perfectly with the definition of Board/Management Information (MANG), which covers changes in the company's board or senior management (advisory boards fall under this scope as they advise management). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns specific personnel/advisory structure changes.
2018-11-20 French
PR in English
Board/Management Information Classification · 98% confidence The document is a press release dated November 20, 2018, announcing the appointment of six experts to the Company's newly formed Strategic Advisory Board (SAB). This announcement concerns changes related to the company's scientific and medical leadership/advisory structure, which falls under the scope of Board/Management Information (MANG). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). It is a specific announcement about key personnel/advisory appointments.
2018-11-20 English
Franchissement de seuils
Major Shareholding Notification Classification · 98% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to "Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)". This type of filing specifically reports when a major shareholder (Wellington Management Group LLP in this case) crosses ownership thresholds (5% in this instance) of the company's capital and voting rights. This directly corresponds to the definition of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2018-11-16 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.